Breaking News on Contract Research, Manufacturing & Clinical Trials

Read more breaking news


News in brief

DEA licenses Pharmatek for controlled substance analysis


Pharmatek Laboratories has received US DEA approval for the analysis of Schedule I to IV controlled substances.

The US Drug Enforcement Agency (DEA) license allows Pharmatek to perform analytical and stability testing of controlled-substance drug products in its non-potent and highly-potent plants. Pharmatek already had a license to develop and manufacture Schedule IV and V products.


"Receipt of this additional registration from the DEA…further validates our facility design, security systems, and procedures for analysis, handling, storage and disposal of controlled substances", said Jeffrey Bibbs, CEO and chief scientific officer at Pharmatek.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...